1. Home
  2. CVM vs ATOS Comparison

CVM vs ATOS Comparison

Compare CVM & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

SELL

Current Price

$1.57

Market Cap

24.1M

Sector

Health Care

ML Signal

SELL

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

SELL

Current Price

$2.00

Market Cap

25.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CVM
ATOS
Founded
1983
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.1M
25.9M
IPO Year
1996
2010

Fundamental Metrics

Financial Performance
Metric
CVM
ATOS
Price
$1.57
$2.00
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$12.50
★ $19.00
AVG Volume (30 Days)
★ 101.5K
56.0K
Earning Date
11-27-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $264,033.00
$1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 65.45
N/A
52 Week Low
$0.89
$0.53
52 Week High
$7.80
$7.56

Technical Indicators

Market Signals
Indicator
CVM
ATOS
Relative Strength Index (RSI) 53.11 37.98
Support Level $1.01 $1.76
Resistance Level $1.80 $2.60
Average True Range (ATR) 0.16 0.18
MACD 0.01 -0.04
Stochastic Oscillator 73.54 25.81

Price Performance

Historical Comparison
CVM
ATOS

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Share on Social Networks: